Revenue from Contracts with Customers

3 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

Revenue from contracts with customers

Note 4 – Revenue from contracts with customers

Disaggregated revenue

The Company provides diagnostic test products, laboratory services to hospitals, clinical laboratories and other healthcare provider customers, and enters into collaboration agreements with government agencies and healthcare providers. The revenues by type of service consist of the following:

	Three Months Ended March 31,
	2022		2021
Product sales	$	366,052	$	613,918
Laboratory services		42,929		97,726
Collaboration revenue		60,764		118,072
Total revenue	$	469,745	$	829,716

Revenues by geography are as follows:

	Three Months Ended March 31,
	2022		2021
Domestic	$	156,410	$	344,008
International		313,335		485,708
Total revenue	$	469,745	$	829,716

Deferred revenue

The Company had no deferred revenue at March 31, 2022 and December 31, 2021.

Contract assets

The Company had approximately $55,505 of contract assets as of March 31, 2022, which are generated when contractual billing schedules differ from revenue recognition timing. The Company had $0 of contract assets as of December 31, 2021. Contract assets represent a conditional right to consideration for satisfied performance obligations that becomes a billed receivable when the conditions are satisfied.

Unsatisfied performance obligations

The Company had no unsatisfied performance obligations related to its contracts with customers at March 31, 2022 and December 31, 2021.